What is First Tracks Biotherapeutics (TRAX) stock price today?

First Tracks Biotherapeutics (TRAX) currently trades at $23.27 per share. The stock has a market capitalization of $821.46M and a P/E ratio of —x.

Is TRAX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, First Tracks Biotherapeutics has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

TRAX

First Tracks Biotherapeutics

NASDAQ: TRAX · HEALTHCARE · BIOTECHNOLOGY

$23.27

-1.57% today

Updated 2026-04-30

Market cap

$821.46M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.71

Dividend yield

—

52W range

$11 – $27

Volume

0.7M

Market cap

$821.46M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.71

Dividend yield

—

52W range

$11 – $27

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$37.00

+59.00%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

Key financials

Revenue Net Income Free Cash Flow

Metric	TTM
Revenue	—
Net income	—
EPS	$-4.71
Free cash flow	—
Profit margin	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TRAX	$821.46M	24	4.3	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

First Tracks Biotherapeutics trades at $23.27. Our Smart Value Score of 24/100 indicates the stock is weak.

Frequently asked questions

What is First Tracks Biotherapeutics's stock price?

First Tracks Biotherapeutics (TRAX) trades at $23.27.

Is First Tracks Biotherapeutics overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of First Tracks Biotherapeutics (TRAX)?

The analyst target price is $37.00, representing +59.0% upside from the current price of $23.27.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-48.90%

Beta—

50D MA$21.27

200D MA$21.27

Shares out0.03B

Float—

Short ratio—

Avg volume0.7M

Performance

1 week+28.14%

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TRAX vs LLY →TRAX vs JNJ →TRAX vs ABBV →Stock screener →